A new treatment for high grade gliomas of the brain.
The data confirmed the fact that repeated administrations of iodine-125 labeled anti-epidermal growth factor receptor 425 is safe and may have benefited the management of primary high grade gliomas of the brain as well as recurrent astrocytomas. At present, a randomized control phase III trial is in the process of being initiated to evaluate the benefits that would accrue in a controlled environment.
Brady
L W
LW
Department of Radiation Oncology, Allegheny University of the Health Sciences Allegheny University Hospitals, Hahnemann, Philadelphia, USA.
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001254:Astrocytoma / Q000401:mortality / Q000628:therapy*; D001932:Brain Neoplasms / Q000401:mortality / Q000628:therapy*; D003131:Combined Modality Therapy; D066246:ErbB Receptors / Q000276:immunology*; D005909:Glioblastoma / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007553:Isotope Labeling; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000628:therapy*; D016019:Survival Analysis